These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 38692630)

  • 1. Reticular epithelial corneal oedema secondary to topical netarsudil drops.
    Kumar VS; Puthuran GV; Radhakrishnan N; Kohli P
    Natl Med J India; 2023; 36(4):274-275. PubMed ID: 38692630
    [No Abstract]   [Full Text] [Related]  

  • 2. Netarsudil-Associated Reticular Corneal Epithelial Edema with Raised Intraocular Pressure.
    Liu KC; Gupta D
    Ophthalmol Glaucoma; 2019; 2(3):166. PubMed ID: 32672585
    [No Abstract]   [Full Text] [Related]  

  • 3. Reticular Corneal Edema or Corneal Honeycombing in Eyes Treated With Netarsudil: A Case Series.
    Moumneh K; Sheybani A; Fellman RL; Godfrey DG; Grover DS
    J Glaucoma; 2020 Jul; 29(7):607-610. PubMed ID: 32398584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transient Reticular Cystic Corneal Epithelial Edema With Topical Netarsudil: A Case Series and Review.
    LoBue SA; Moustafa GA; Vu A; Amin M; Nguyen T; Goyal H
    Cornea; 2021 Aug; 40(8):1048-1054. PubMed ID: 33369939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reticular Epithelial Edema in Edematous Corneas Treated with Netarsudil.
    Fernandez MM
    Ophthalmology; 2018 Nov; 125(11):1709. PubMed ID: 30318038
    [No Abstract]   [Full Text] [Related]  

  • 6. Reticular Epithelial Edema: An Uncommon Side Effect of ROCK/NET Inhibitor Netarsudil.
    Chen H; McMillin JC; Frankfort BJ; Al-Mohtaseb Z
    J Glaucoma; 2020 Nov; 29(11):e124-e126. PubMed ID: 32826765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Patient With Glaucoma With Corneal Edema.
    Chen TC; Jurkunas U; Chodosh J
    JAMA Ophthalmol; 2020 Aug; 138(8):917-918. PubMed ID: 32584374
    [No Abstract]   [Full Text] [Related]  

  • 8. Honeycomb Epithelial Edema Associated With Rho Kinase Inhibition: A Case Series and Review of the Literature.
    Lyons LJ; Wu KY; Baratz KH; Sit AJ
    Cornea; 2022 Feb; 41(2):243-248. PubMed ID: 35037906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2).
    Kahook MY; Serle JB; Mah FS; Kim T; Raizman MB; Heah T; Ramirez-Davis N; Kopczynski CC; Usner DW; Novack GD;
    Am J Ophthalmol; 2019 Apr; 200():130-137. PubMed ID: 30653957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reticular Bullous Epithelial Edema in Corneas Treated with Netarsudil: A Case Series.
    Wisely CE; Liu KC; Gupta D; Carlson AN; Asrani SG; Kim T
    Am J Ophthalmol; 2020 Sep; 217():20-26. PubMed ID: 32289295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Netarsudil Ophthalmic Solution 0.02%: First Global Approval.
    Hoy SM
    Drugs; 2018 Mar; 78(3):389-396. PubMed ID: 29453668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ocular factors relevant to anti-glaucomatous eyedrop-related keratoepitheliopathy.
    Soltau JB
    J Glaucoma; 2004 Aug; 13(4):348; author reply 348. PubMed ID: 15226666
    [No Abstract]   [Full Text] [Related]  

  • 13. Reversible Corneal Endothelial Abnormalities With Netarsudil.
    Tanna AP; Esfandiari H; Teramoto K
    J Glaucoma; 2020 Jun; 29(6):e41-e43. PubMed ID: 32224803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corneal Hemorrhage Associated with Netarsudil in the Setting of Corneal Neovascularization.
    Asanad S; Zhang R; Saeedi OJ
    Ophthalmol Glaucoma; 2020; 3(5):392. PubMed ID: 32980044
    [No Abstract]   [Full Text] [Related]  

  • 15. Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma.
    Lin CW; Sherman B; Moore LA; Laethem CL; Lu DW; Pattabiraman PP; Rao PV; deLong MA; Kopczynski CC
    J Ocul Pharmacol Ther; 2018; 34(1-2):40-51. PubMed ID: 28609185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of 0.02% netarsudil ophthalmic solution on intraocular pressure of normotensive dogs.
    Yang VY; Miller PE; Keys DA; La Croix NC
    Vet Ophthalmol; 2021 Mar; 24 Suppl 1():87-95. PubMed ID: 31908139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, Double-Masked, Pilot Study of Netarsudil 0.02% Ophthalmic Solution for Treatment of Corneal Edema in Fuchs Dystrophy.
    Price MO; Price FW
    Am J Ophthalmol; 2021 Jul; 227():100-105. PubMed ID: 33737034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-Daily Netarsudil Versus Twice-Daily Timolol in Patients With Elevated Intraocular Pressure: The Randomized Phase 3 ROCKET-4 Study.
    Khouri AS; Serle JB; Bacharach J; Usner DW; Lewis RA; Braswell P; Kopczynski CC; Heah T;
    Am J Ophthalmol; 2019 Aug; 204():97-104. PubMed ID: 30862500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Netarsudil and latanoprost ophthalmic solution for the reduction of intraocular pressure in open-angle glaucoma or ocular hypertension.
    Aref AA; Geyman LS; Zakieh AR; Alotaibi HM
    Expert Rev Clin Pharmacol; 2019 Dec; 12(12):1073-1079. PubMed ID: 31842637
    [No Abstract]   [Full Text] [Related]  

  • 20. Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2.
    Asrani S; Bacharach J; Holland E; McKee H; Sheng H; Lewis RA; Kopczynski CC; Heah T
    Adv Ther; 2020 Apr; 37(4):1620-1631. PubMed ID: 32166538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.